DNA copy number alterations mark disease progression in paediatric chronic myeloid leukaemia

There is no fulltext present in this item.

Title:	DNA copy number alterations mark disease progression in paediatric chronic myeloid leukaemia
Author(s):	Sligte, N.E. van der; Krumbholz, M.; Pastorczak, A.; Scheijen, B.; Tauer, J.T.; Nowasz, C.; Sonneveld, E.; Bock, G.H. de; Boer, T.G. Meeuwsen-de; Reijmersdal, S. van; Kuiper, R.P. ; Bradtke, J.; Metzler, M.; Suttorp, M.; Bont, E.S. de; Leeuwen, F.N. van
Publication year:	2014
Source:	British Journal of Haematology, vol. 166, iss. 2, (2014), pp. 250-253
ISSN:	0007-1048
DOI:	https://doi.org/10.1111/bjh.12850
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/137732
Display more details
Subject:	Radboudumc 14: Tumours of the digestive tract RIMLS: Radboud Institute for Molecular Life Sciences Radboudumc 2: Cancer development and immune defence RIMLS: Radboud Institute for Molecular Life Sciences
Organization:	Human Genetics Paediatrics - OUD tm 2017 Laboratory Medicine
Journal title:	British Journal of Haematology
Volume:	vol. 166
Issue:	iss. 2
Page start:	p. 250
Page end:	p. 253
Abstract:	Early recognition of children with chronic phase chronic myeloid leukaemia (CML-CP) at risk for developing a lymphoid blast crisis (LyBC) is desirable, because therapy options in CML-LyBC are limited. We used Multiplex Ligation-dependent Probe Amplification to determine whether B-cell lymphoid leukaemia-specific copy number alterations (CNAs) (e.g. IKZF1, PAX5, CDKN2A deletions) could be detected in CML-CP and may be used to predict disease progression to LyBC. CNAs were detected in all patients with CML-LyBC, but in none of the 77 patients with CML-CP. Based on this study we conclude that CNAs remain a hallmark of disease progression.